NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?Zacks Investment Research · 2 days ago
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.The Motley Fool · 3 days ago
48,696 Novo Nordisk A/S $NVO Shares Sold by Carnegie Investment CounselDefense World · 3 days ago
Where Will Novo Stock Be in 10 Years?The Motley Fool · 3 days ago
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?Zacks Investment Research · 3 days ago
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight LossZacks Investment Research · 3 days agoNovo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.82 | $0.96 | Beat |
| May 6, 2026 | $0.87 | $1.04 | Beat |
| Feb 3, 2026 | $0.90 | $1.00 | Beat |
| Nov 5, 2025 | $0.77 | $1.02 | Beat |
| Aug 6, 2025 | $0.93 | $0.97 | Beat |
| May 7, 2025 | $0.92 | $0.92 | Beat |